AMSilk Partners with Mercedes-Benz to Present a Sustainable Bio-Based Product
The use of a biotechnology-based and certified-vegan…
EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)
OSLO/LONDON, 22 December 2021: Christmas came early at EXACT…
Novo Holdings invests EUR 86 million in 21st.BIO, a new bioindustrial scale-up company building on technology base from Novozymes
COPENHAGEN, DENMARK — Novo Holdings, a leading international…
EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®
OSLO/ LONDON: 21 December 2021: EXACT Therapeutics AS (“EXACT-Tx”…
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Chord Therapeutics was launched by Omega Funds in October…
Futura provides US regulatory and commercial update for MED3000
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Study Supports Ongoing Phase 3 Program and Planned NDA Submission
LONDON…
Novo Nordisk Fonden: New international research center to drive future stem cell-derived medicines
Stem cell medicine is delivering hope for new treatments across…
Novo Nordisk Foundation – New international research center to drive future stem cell-derived medicines
A grant from the Novo Nordisk Foundation of up to 300 million…
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
TARPEYO (budesonide) delayed release capsules is the first…
2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon
Management of Destiny Pharma (DEST), the AIM listed infection…
ViCentra closes EUR 65M (USD 74M) Series C funding to expand the footprint of world’s smallest insulin pump across Europe
New investor, Partners in Equity – joins existing investors…
Depixus Raises USD 35.4M in Series A Financing
The financing will support development of a commercial instrument…
Biocomposites year of international growth and product advancement
Expansion into new geographies and enhanced approval for STIMULAN…
Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data
Egetis concludes, based on recent regulatory interactions,…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
